2-(6-氟吡啶-2-基)乙腈 | 312325-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(6-氟吡啶-2-基)乙腈
• 英文名称: (6-fluoropyridin-2-yl)acetonitrile
• 英文别名: (6-fluoropyridine-2-yl)acetonitrile；2-(6-fluoropyridin-2-yl)acetonitrile
• CAS: 312325-71-6
• 化学式: C₇H₅FN₂
• mdl: MFCD09924020
• 分子量: 136.129
• InChiKey: MVFWEETVHOUHOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(6-氟吡啶-2-基)乙腈 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 32.0h， 生成
  参考文献：
  名称：

  Discovery of protein–protein binding disruptors using multi-component condensations small molecules

  摘要：

  A series of small molecule compounds interfering with the binding process of VEGF and NRP1 has been identified and further optimized. Full synthetic details as well as SAR are reported which demonstrate that expeditious MCC-based syntheses may lead to valuable molecules addressing challenging targets such as protein-protein interactions. Preliminary functional assay data confirm that these compounds may be further developed toward drug candidates. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.014
• 作为产物：
  描述：

  2,6-二氟吡啶 、 乙腈 在 正丁基锂 作用下， 生成 2-(6-氟吡啶-2-基)乙腈
  参考文献：
  名称：

  [EN] PYRIMIDONE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ PYRIMIDONE ET SON UTILISATION
  [ZH] 嘧啶酮化合物及其用途

  摘要：

  提出了一种有效抑制MAT2A的新化合物，其为式I所示化合物，或者式I所示化合物的互变异构体、立体异构体、水合物、溶剂化物、药学可接受的盐或前药。其中，W是-C(R3)＝或-N＝；X是-C(R4)＝或-N＝；Y是-C(R5)＝；Z是-C(R6)＝或-N＝；R1、R2、R3、R4、R5、R6的定义如说明书中所述。

  公开号：

  WO2022222911A1

文献信息

• From CO₂ to 4<i>H</i>-Quinolizin-4-ones: A One-Pot Multicomponent Approach via Ag₂O/Cs₂CO₃ Orthogonal Tandem Catalysis
  作者：Chao-Chen Dong、Jun-Feng Xiang、Li-Jin Xu、Han-Yuan Gong

  DOI：10.1021/acs.joc.8b01206

  日期：2018.8.17

  report relatively simple and cost-effective orthogonal tandem catalysis, namely Ag2O in conjunction with Cs2CO3 serves to promote a multicomponent tandem reaction forming two new C–C and one new C–N bonds. 4H-Quinolizin-4-ones, key skeletal components in a variety of biologically active molecules, were obtained with yields up to 99%. The present approach features a broad substrate scope and mild reaction

  本文使用二氧化碳作为C1的前体，我们报告了相对简单且经济高效的正交串联催化，即Ag 2 O与Cs 2 CO 3结合可促进多组分串联反应，形成两个新的C–C和一个新的C– N个债券。获得了4 H -Quinolizin-4-ones，这是多种生物活性分子中的关键骨架成分，产率高达99％。本方法具有广泛的底物范围和温和的反应条件，并受益于使用具有成本效益的反应和催化剂。
• Palladium-catalyzed direct deprotonative arylation of 2-pyridylacetonitriles: Facile synthesis of alpha-aryl-2-pyridylacetonitrile
  作者：Bo Yin、Yu-Feng Du、Yan-Zuo Chen、Xiaohuan Li、Dong-Mei Fang、Feng Gao

  DOI：10.1016/j.tetlet.2020.152534

  日期：2020.11

  α-Aryl-2-pyridylacetonitrile, an important chemical intermediate, was synthesized via direct deprotonative arylation of 2-pyridylacetonitrile with aryl bromides. Pd(OAc)2/NixantPhos-based catalysis system promoted this arylation reaction to furnish diverse α-aryl-2-pyridylacetonitrile derivatives in wide range function group tolerance and high yield (80%-97%).

  α-芳基-2-吡啶基乙腈是一种重要的化学中间体，是通过2-吡啶基乙腈与芳基溴的直接去质子化芳基化反应合成的。基于Pd（OAc）2 / NixantPhos的催化体系促进了这种芳基化反应，从而以宽泛的官能团耐受性和高收率（80％-97％）提供了多种α-芳基-2-吡啶基乙腈衍生物。
• [EN] PYRIMIDONE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ PYRIMIDONE ET SON UTILISATION<br/>[ZH] 嘧啶酮化合物及其用途
  申请人：WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY

  公开号：WO2022222911A1

  公开（公告）日：2022-10-27

  提出了一种有效抑制MAT2A的新化合物，其为式I所示化合物，或者式I所示化合物的互变异构体、立体异构体、水合物、溶剂化物、药学可接受的盐或前药。其中，W是-C(R3)＝或-N＝；X是-C(R4)＝或-N＝；Y是-C(R5)＝；Z是-C(R6)＝或-N＝；R1、R2、R3、R4、R5、R6的定义如说明书中所述。
• Skerlj; Bogucki; Bridger, Synlett, 2000, # 10, p. 1488 - 1490
  作者：Skerlj、Bogucki、Bridger

  DOI：——

  日期：——
• Discovery of protein–protein binding disruptors using multi-component condensations small molecules
  作者：Karim Bedjeguelal、Hugues Bienaymé、Antoine Dumoulin、Stéphane Poigny、Philippe Schmitt、Eric Tam

  DOI：10.1016/j.bmcl.2006.05.014

  日期：2006.8

  A series of small molecule compounds interfering with the binding process of VEGF and NRP1 has been identified and further optimized. Full synthetic details as well as SAR are reported which demonstrate that expeditious MCC-based syntheses may lead to valuable molecules addressing challenging targets such as protein-protein interactions. Preliminary functional assay data confirm that these compounds may be further developed toward drug candidates. (c) 2006 Elsevier Ltd. All rights reserved.